FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2318841710> ?p ?o ?g. }

• W2318841710 endingPage "A482" @default.
• W2318841710 startingPage "A482.1" @default.
• W2318841710 abstract "<h3>Background</h3> The choice of composite clinical assessment tools in lupus clinical trials is expanding, but it is important to understand the differences between what these endpoints measure. The SLE Responder Index (SRI) was developed for the successful Phase III belimumab (BLISS) program which defines response as ≥ 4 (SRI-4) or 5 (SRI-5) point decrease in SLEDAI, no new BILAG A (severe disease) or 2 new B (moderate disease) organ scores plus increase in PGA of < 0.3 points (10% of scale). The best treatment corrected difference achieved with SRI-4 were 9.8% (1), and 14.4% (2) in the two phase III BLISS trials. The BICLA was tested in a Phase II study of epratuzumab (EMBLEM) with response defined by at least one grade improvement in all BILAG moderate or severe scores, no new BILAG A or 2 new B scores, no increase in SLEDAI, <10% worsening in PGA and no off-protocol treatment. Optimal treatment corrected differences in this trial was 24.8% (3). A comparison of BICLA and SRI has been reported using EMBLEM data (4), but was complicated by scoring of many 8 point features on SLEDAI which are not common in lupus. BICLA data from the BLISS studies have not been reported. <h3>Objectives</h3> To compare the SRI and BICLA to a physician-weighted definition of improvement in the BOLD study <h3>Methods</h3> The BOLD study was designed to test the impact of clinical, biologic and background treatment variables on lupus trials and scoring of 8 point SLEDAI features were rare. 41 patients entered with active disease (minimum SLEDAI of 6 or two BILAG B scores) in a single study center, then background immune suppressives were withdrawn, brief intramuscular steroids given until improvement, and patients followed until they flared. BOLD improvement was defined as either a 4 point drop in SLEDAI or one grade improvement in BILAG and required physician determination of clinically significant improvement. This allowed for simpler quantitative criteria, anchored by clinician judgment. <h3>Results</h3> At the improving visit, the mean decrease from baseline in PGA was 1.06 ± 0.38 (scale 0-3). Count of responders by SRI and BICLA are shown in the table below with McNemar’s test p-value for comparisons to the BOLD (physician-weighted) definition of improvement. <h3>Conclusions</h3> The BICLA was more likely to agree with a physician weighted definition of improvement than SRI, and less likely to score a physician designated flare visit as improvement. Differences in treatment efficacy, clinical trial design, and adjudication of trial endpoints may have accounted for the improved discrimination seen between treatment groups in the EMBLEM study (using BICLA) compared to the BLISS studies (using SRI). However, if further validated, these observations from BOLD may be helpful in optimizing the choice of clinical endpoints for future lupus trials. <h3>References</h3> Navarra SV, et al. Lancet. 2011;377:721–731. Furie R, et al. Arthritis Rheum. 2011;63:3918–3930. Wallace DJ, et al. Ann Rheum Dis 2013;00:1–8. Petri M, et al. ACR 2011; 1378. <b>Disclosure of Interest</b>: None Declared" @default.
• W2318841710 created "2016-06-24" @default.
• W2318841710 creator A5005521984 @default.
• W2318841710 creator A5009487314 @default.
• W2318841710 creator A5014587154 @default.
• W2318841710 creator A5018243352 @default.
• W2318841710 creator A5026969378 @default.
• W2318841710 creator A5045283443 @default.
• W2318841710 date "2013-06-01" @default.
• W2318841710 modified "2023-09-27" @default.
• W2318841710 title "FRI0318 Comparison of lupus trial endpoints to a physician-weighted definition of improvement in the biomarkers of lupus disease (BOLD) study suggests improved discrimination using bicla (bilag based composite lupus assessment) vs sri (sle responder index)" @default.
• W2318841710 doi "https://doi.org/10.1136/annrheumdis-2013-eular.1445" @default.
• W2318841710 hasPublicationYear "2013" @default.
• W2318841710 type Work @default.
• W2318841710 sameAs 2318841710 @default.
• W2318841710 citedByCount "0" @default.
• W2318841710 crossrefType "journal-article" @default.
• W2318841710 hasAuthorship W2318841710A5005521984 @default.
• W2318841710 hasAuthorship W2318841710A5009487314 @default.
• W2318841710 hasAuthorship W2318841710A5014587154 @default.
• W2318841710 hasAuthorship W2318841710A5018243352 @default.
• W2318841710 hasAuthorship W2318841710A5026969378 @default.
• W2318841710 hasAuthorship W2318841710A5045283443 @default.
• W2318841710 hasConcept C105795698 @default.
• W2318841710 hasConcept C126322002 @default.
• W2318841710 hasConcept C141341695 @default.
• W2318841710 hasConcept C159654299 @default.
• W2318841710 hasConcept C170286685 @default.
• W2318841710 hasConcept C1862650 @default.
• W2318841710 hasConcept C186282968 @default.
• W2318841710 hasConcept C203014093 @default.
• W2318841710 hasConcept C203092338 @default.
• W2318841710 hasConcept C2776912625 @default.
• W2318841710 hasConcept C2778453870 @default.
• W2318841710 hasConcept C2779134260 @default.
• W2318841710 hasConcept C2781205201 @default.
• W2318841710 hasConcept C33923547 @default.
• W2318841710 hasConcept C535046627 @default.
• W2318841710 hasConcept C71924100 @default.
• W2318841710 hasConceptScore W2318841710C105795698 @default.
• W2318841710 hasConceptScore W2318841710C126322002 @default.
• W2318841710 hasConceptScore W2318841710C141341695 @default.
• W2318841710 hasConceptScore W2318841710C159654299 @default.
• W2318841710 hasConceptScore W2318841710C170286685 @default.
• W2318841710 hasConceptScore W2318841710C1862650 @default.
• W2318841710 hasConceptScore W2318841710C186282968 @default.
• W2318841710 hasConceptScore W2318841710C203014093 @default.
• W2318841710 hasConceptScore W2318841710C203092338 @default.
• W2318841710 hasConceptScore W2318841710C2776912625 @default.
• W2318841710 hasConceptScore W2318841710C2778453870 @default.
• W2318841710 hasConceptScore W2318841710C2779134260 @default.
• W2318841710 hasConceptScore W2318841710C2781205201 @default.
• W2318841710 hasConceptScore W2318841710C33923547 @default.
• W2318841710 hasConceptScore W2318841710C535046627 @default.
• W2318841710 hasConceptScore W2318841710C71924100 @default.
• W2318841710 hasIssue "Suppl 3" @default.
• W2318841710 hasLocation W23188417101 @default.
• W2318841710 hasOpenAccess W2318841710 @default.
• W2318841710 hasPrimaryLocation W23188417101 @default.
• W2318841710 hasRelatedWork W2000779116 @default.
• W2318841710 hasRelatedWork W2117421560 @default.
• W2318841710 hasRelatedWork W2129537748 @default.
• W2318841710 hasRelatedWork W2315366533 @default.
• W2318841710 hasRelatedWork W2330531829 @default.
• W2318841710 hasRelatedWork W2735474972 @default.
• W2318841710 hasRelatedWork W2755059959 @default.
• W2318841710 hasRelatedWork W2755535356 @default.
• W2318841710 hasRelatedWork W2755931468 @default.
• W2318841710 hasRelatedWork W2762168124 @default.
• W2318841710 hasRelatedWork W2794259934 @default.
• W2318841710 hasRelatedWork W2901844031 @default.
• W2318841710 hasRelatedWork W2907749529 @default.
• W2318841710 hasRelatedWork W2908749744 @default.
• W2318841710 hasRelatedWork W2909082860 @default.
• W2318841710 hasRelatedWork W2947471477 @default.
• W2318841710 hasRelatedWork W2990706997 @default.
• W2318841710 hasRelatedWork W2996805625 @default.
• W2318841710 hasRelatedWork W3013431424 @default.
• W2318841710 hasRelatedWork W3164024750 @default.
• W2318841710 hasVolume "72" @default.
• W2318841710 isParatext "false" @default.
• W2318841710 isRetracted "false" @default.
• W2318841710 magId "2318841710" @default.
• W2318841710 workType "article" @default.